Index RUT
P/E -
EPS (ttm) -1.05
Insider Own 21.18%
Shs Outstand 57.82M
Perf Week 6.59%
Market Cap 850.87M
Forward P/E 146.92
EPS next Y 0.09
Insider Trans -2.23%
Shs Float 49.35M
Perf Month 17.56%
Income -60.00M
PEG -
EPS next Q -0.05
Inst Own 79.31%
Short Float 9.68%
Perf Quarter 0.52%
Sales 219.70M
P/S 3.87
EPS this Y 55.00%
Inst Trans 0.63%
Short Ratio 7.46
Perf Half Y 52.53%
Book/sh 0.30
P/B 45.89
EPS next Y 132.84%
ROA -31.06%
Short Interest 4.78M
Perf Year 37.55%
Cash/sh 1.55
P/C 8.78
EPS next 5Y 16.50%
ROE -472.61%
52W Range 7.07 - 15.43
Perf YTD 29.06%
Dividend Est. -
P/FCF -
EPS past 5Y 10.81%
ROI -41.69%
52W High -11.94%
Beta 1.34
Dividend TTM -
Quick Ratio 2.96
Sales past 5Y 44.65%
Gross Margin 66.85%
52W Low 92.22%
ATR (14) 0.52
Dividend Ex-Date -
Current Ratio 3.21
EPS Y/Y TTM 18.05%
Oper. Margin -15.05%
RSI (14) 62.09
Volatility 3.68% 3.95%
Employees 273
Debt/Eq 6.87
Sales Y/Y TTM 40.45%
Profit Margin -27.31%
Recom 1.12
Target Price 22.29
Option/Short Yes / Yes
LT Debt/Eq 6.81
EPS Q/Q 14.85%
Payout -
Rel Volume 1.11
Prev Close 13.70
Sales Surprise 3.61%
EPS Surprise 45.49%
Sales Q/Q 42.21%
Earnings May 07 AMC
Avg Volume 640.48K
Price 13.59
SMA20 8.62%
SMA50 3.99%
SMA200 24.42%
Trades
Volume 712,094
Change -0.80%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-29-24 Upgrade
Barclays
Equal Weight → Overweight
$10 → $16
Jun-23-22 Initiated
Needham
Buy
$18
May-12-22 Upgrade
Barclays
Underweight → Equal Weight
$8 → $10
Jan-20-22 Upgrade
Truist
Hold → Buy
$11
May-06-21 Upgrade
Mizuho
Neutral → Buy
$15
Apr-08-21 Reiterated
H.C. Wainwright
Buy
$20 → $22
Feb-24-21 Downgrade
Truist
Buy → Hold
$12
Jul-07-20 Downgrade
Mizuho
Buy → Neutral
$8 → $3
Feb-06-20 Resumed
Mizuho
Buy
Nov-26-19 Initiated
SVB Leerink
Outperform
$25
Sep-05-19 Resumed
Mizuho
Buy
$30
Jun-28-19 Initiated
Wells Fargo
Market Perform
$16
Jun-11-19 Initiated
Barclays
Underweight
$13
Mar-20-19 Initiated
SunTrust
Buy
$30
Feb-14-19 Initiated
H.C. Wainwright
Buy
$37
Jan-29-19 Initiated
Stifel
Buy
$27
Show Previous Ratings
May-16-24 02:54AM
02:54AM
May-15-24 08:30AM
May-10-24 06:55PM
09:10AM
11:09AM
Loading…
May-08-24 11:09AM
07:24AM
(Thomson Reuters StreetEvents)
03:53AM
May-07-24 08:58PM
06:35PM
05:46PM
04:05PM
May-02-24 07:37AM
Apr-23-24 04:30PM
Apr-21-24 10:39AM
04:05PM
Loading…
Apr-17-24 04:05PM
Apr-12-24 04:05PM
Mar-26-24 08:00AM
Mar-14-24 07:04AM
Mar-13-24 09:55AM
Mar-11-24 07:00AM
Mar-08-24 04:05PM
03:24PM
12:30PM
(Thomson Reuters StreetEvents)
Mar-07-24 10:34PM
09:53PM
04:05PM
Mar-04-24 08:28PM
Mar-01-24 08:30AM
Feb-27-24 08:30AM
04:30PM
Loading…
Feb-22-24 04:30PM
Feb-09-24 04:05PM
Feb-02-24 09:10PM
Jan-16-24 05:28PM
Jan-12-24 04:23PM
Jan-09-24 06:21PM
Jan-04-24 04:05PM
Dec-20-23 08:00AM
Dec-08-23 04:30PM
Nov-13-23 09:08AM
Nov-10-23 05:16PM
Nov-07-23 04:16PM
Nov-06-23 08:45AM
Nov-01-23 08:45AM
Oct-25-23 08:45AM
08:45AM
Oct-08-23 06:41PM
Sep-29-23 04:05PM
Sep-13-23 04:10PM
Sep-09-23 01:03PM
Sep-03-23 05:29AM
Aug-29-23 08:45AM
Aug-27-23 07:20PM
Aug-23-23 06:53PM
Aug-21-23 08:45AM
Aug-08-23 09:15AM
08:45AM
Aug-02-23 05:45PM
04:05PM
Jul-27-23 11:42AM
08:45AM
Jul-26-23 10:02AM
08:45AM
Jul-19-23 08:45AM
Jul-15-23 07:30AM
Jun-29-23 09:00AM
Jun-22-23 08:45AM
Jun-08-23 04:05PM
Jun-02-23 06:38AM
May-16-23 01:44PM
May-09-23 05:25PM
04:01PM
04:01PM
May-05-23 01:37PM
Apr-17-23 11:05AM
Apr-04-23 10:39AM
Mar-11-23 06:38AM
Mar-09-23 10:12AM
(Thomson Reuters StreetEvents)
Mar-08-23 05:35PM
04:05PM
Feb-28-23 08:45AM
Feb-27-23 08:45AM
Feb-22-23 08:45AM
Feb-10-23 11:07AM
Jan-31-23 08:45AM
Jan-30-23 12:02PM
07:09AM
Jan-28-23 08:00AM
Jan-23-23 09:00AM
08:00AM
Jan-20-23 01:54PM
Jan-19-23 01:15PM
Jan-18-23 08:45AM
Jan-03-23 10:03AM
Dec-08-22 08:45AM
Dec-07-22 10:00AM
09:17AM
Nov-10-22 05:57AM
Nov-08-22 06:25PM
04:05PM
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GILL DAVID N Director May 14 '24 Sale 12.60 6,718 84,654 33,964 May 15 05:20 PM Malik Vikram Director May 13 '24 Sale 12.93 28,000 362,012 254,014 May 15 05:19 PM GILL DAVID N Director May 13 '24 Sale 12.72 3,643 46,356 40,682 May 15 05:20 PM MOATAZEDI DAVID See Remarks May 10 '24 Sale 12.72 16,051 204,127 673,563 May 14 08:56 PM Avelar Rui See Remarks May 10 '24 Sale 12.72 3,441 43,761 368,847 May 14 08:56 PM Beaver Sandra Chief Financial Officer May 10 '24 Sale 12.72 2,423 30,814 151,778 May 14 08:55 PM MOATAZEDI DAVID See Remarks Mar 27 '24 Sale 13.86 6,236 86,431 689,614 Mar 29 07:08 PM MOATAZEDI DAVID See Remarks Mar 19 '24 Sale 13.92 96,566 1,344,604 695,850 Mar 21 06:08 PM Avelar Rui See Remarks Mar 19 '24 Sale 13.92 27,603 384,350 372,288 Mar 21 06:09 PM Beaver Sandra Chief Financial Officer Mar 19 '24 Sale 13.92 5,672 78,978 154,201 Mar 21 06:09 PM MOATAZEDI DAVID See Remarks Feb 22 '24 Sale 13.08 7,706 100,804 792,416 Feb 23 08:27 PM Beaver Sandra Chief Financial Officer Feb 22 '24 Sale 13.08 1,821 23,821 159,873 Feb 23 08:27 PM Avelar Rui See Remarks Feb 22 '24 Sale 13.08 1,821 23,821 399,891 Feb 23 08:27 PM Parschauer Karah Herdman Director Jan 30 '24 Sale 13.14 11,931 156,733 31,243 Feb 02 04:57 PM MOATAZEDI DAVID See Remarks Dec 08 '23 Sale 9.73 31,300 304,505 603,944 Dec 08 06:15 PM MOATAZEDI DAVID See Remarks Dec 06 '23 Sale 10.09 51,348 517,891 635,244 Dec 08 06:15 PM Medytox Inc. Former 10% Owner Oct 16 '23 Sale 7.50 1,690,663 12,679,972 3,381,326 Oct 18 04:21 PM Beaver Sandra Chief Financial Officer Sep 06 '23 Sale 9.70 3,178 30,827 113,368 Sep 08 08:54 PM MOATAZEDI DAVID See Remarks Aug 16 '23 Sale 10.27 14,778 151,770 686,592 Aug 16 08:25 PM Beaver Sandra Chief Financial Officer Aug 16 '23 Sale 10.27 2,211 22,707 116,546 Aug 16 08:25 PM Avelar Rui See Remarks Aug 16 '23 Sale 10.27 2,211 22,707 353,386 Aug 16 08:25 PM Malik Vikram Director Aug 15 '23 Buy 7.41 174,967 1,296,505 275,550 Aug 15 04:34 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite